In prepubertal short children with GH deficiency, intranasal GHRP‑2 at low and high dose did not change growth rate (height SD score) over 48 weeks versus placebo.
In plain wordsIn short children with GH deficiency, GHRP‑2 nasal spray did not change growth compared with placebo over 48 weeks.
- Peptide
- GHRP-2
- Outcome
- No significant changeChange in height SD score after 48 weeks
- Study
n = 124
- Comparator
- Placebo
- Outcome group
- Growth hormone and IGF-1 · Endocrine and hormones
- Studied dose
- 50 or 100 µg (low) and 100 or 200 µg (high) by body weight, twice daily · intranasal spray · 48 weeksAs given in this study (human).
Measurements
- Change in height SD score
- 0.07 SD
- placebo
- Change in height SD score
- 0.03 SD
- GHRP-2 low dose
- Change in height SD score
- 0.02 SD
- GHRP-2 high dose
Source sentences
The changes in the mean height SD scores (mean growth rate) after 48 wk of treatment in the P, L and H groups were 0.07 SD, 0.03 SD, and 0.02 SD, respectively, and thus no significant differences was observed among the 3 groups.
1 context sentence(design, population, supporting numbers)
This study involved 126 prepubertal short children (81 males, 45 females) with a height SD score of -2 SD or less, who had been diagnosed as having GHD based on GH stimulation tests, and in whom the serum GH concentrations increased up to 9 ng/ml after preliminary administration of an intranasal GHRP-2 spray.